

Insights: Publications

The Fast and the Furious: Article 76 Proceedings in China Proceed with Speed

Kilpatrick Townsend MEMO|Biopharma Industry Blog

July 1, 2022

Written by **Yifan Mao** and **April Abele Isaacson**

Article 76 of the Fourth Amendment to the Chinese Patent Law links regulatory approval of a generic drug and patent protection of the brand-name drug. It establishes a legal framework for resolving drug patent disputes before approval of the generic drug product similar to the Hatch-Waxman Act in the United States.

Related People



Yifan Mao

t 650.324.6311

ymao@ktslaw.com



April Abele Isaacson

t 415.273.8306

aisaacson@ktslaw.com